Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - vincristine sulfate 1 mg/ml (expressed on anhydrous basis);   - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml (expressed on anhydrous basis)   excipient: acetic acid mannitol methyl hydroxybenzoate propyl hydroxybenzoate sodium acetate trihydrate water for injection

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - vincristine sulfate 1 mg/ml;   - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml  

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - vincristine is effective in hodgkins disease and other lymphomas. in hodgkins disease it is effective for the advanced stages (iii and iv) when used in the mopp regime (mechlorethamine, oncovin, prednisone, procarbazine). in non-hodgkins lymphomas, vincristine is an important agent, particularly when used with cyclophosphamide, bleomycin, doxorubicin and prednisone. vincristine is also effective in lymphocytic leukemia. beneficial responses have been reported in patients with a variety of other neoplasms, particularly wilms tumour, neuroblastoma, brain tumours, rhabdomyosarcoma and carcinomas of the breast, bladder, and the female and male reproductive systems.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sodium hydroxide; sulfuric acid; water for injections - vincristine is effective in hodgkins disease and other lymphomas. in hodgkins disease it is effective for the advanced stages (iii and iv) when used in the mopp regime (mechlorethamine, oncovin, prednisone, procarbazine). in non-hodgkins lymphomas, vincristine is an important agent, particularly when used with cyclophosphamide, bleomycin, doxorubicin and prednisone. vincristine is also effective in lymphocytic leukemia. beneficial responses have been reported in patients with a variety of other neoplasms, particularly wilms tumour, neuroblastoma, brain tumours, rhabdomyosarcoma and carcinomas of the breast, bladder, and the female and male reproductive systems.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - vincristine sulfate - solution for injection - 1 mg/ml

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - vincristine sulfate - solution for injection - 1 mg/ml

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vincristine sulfate, quantity: 1 mg - injection, powder for - excipient ingredients: lactose monohydrate; water for injections - oncovin is indicated in acute leukaemia. it has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, wilms' tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung, and gynaecologic tumours of childhood. patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment may respond to oncovin. current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single-agent treatment. thus oncovin is often chosen as part of polychemotherapy because of lack of significant bone-marrow suppression (at recommended doses) and because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. in recent years, multiple-agent regimens have been developed for the treatment of a variety of malignant disorders in children. paediatric patients with neuroblastoma, osteogenic sarcoma, ewing's sarcoma, rhabdomyosarcoma, wilms' tumour, hodgkin's disease, non-hodgkin's lymphomas, embryonal carcinoma of the ovaries, and rhabdomyosarcoma of the uterus should be considered candidates for such polychemotherapy treatment. close cooperation among oncologists, paediatricians, radiologists, and surgeons is required in order to achieve the best possible results. patients with true idiopathic thrombocytopenic purpura refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to oncovin, but the drug is not recommended as primary treatment for this disorder. recommended weekly doses of oncovin given for 3 to 4 weeks have produced permanent remissions in some patients. if patients fail to respond after 3 to 6 doses, it is unlikely that there will be any results with additional doses.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vincristine sulfate, quantity: 1 mg - injection, powder for - excipient ingredients: lactose monohydrate - oncovin is indicated in acute leukaemia. it has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas(lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, wilms' tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung, and gynaecologic tumours of childhood. patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment may respond to oncovin. current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single-agent treatment. thus oncovin is often chosen as part of polychemotherapy becau

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 80; sodium hydroxide; sorbitol; water for injections - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs in doses not usually requiring bone marrow transplantation. to reduce the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with nonmyeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, to reduce the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia. in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 80; sodium hydroxide; sorbitol; water for injections - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs in doses not usually requiring bone marrow transplantation. to reduce the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with nonmyeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, to reduce the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia. in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.